Clinical Trial Update: Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating mesenchymal cell therapy for Osteogenesis Imperfecta (including Type III) is not yet recruiting. The sponsor is Emor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteogenesis Imperfecta
• Osteogenesis Imperfecta Type Iii

Drugs mentioned

• Mesenchymal Cell Therapy

Snippet

Sponsor: Emory University | Conditions: Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING